Almirall SA – Strategic Advances in Pediatric Dermatology and Global Expansion

Almirall SA (ALM) has confirmed a significant milestone in its dermatology portfolio with the top‑line results of the Phase 3 ADorable‑1 trial for lebrikizumab (EBGLYSS). The study, covering children and adolescents aged 6 months to <18 years with moderate‑to‑severe atopic dermatitis (AD), achieved both co‑primary and key secondary efficacy endpoints at Week 16. Sixty‑three percent of participants attained meaningful skin improvement (EASI‑75), while 44 % reached clear or almost clear skin (IGA 0/1). Notably, 39 % achieved near‑complete clearance (EASI‑90) and 35 % reported significant itch relief (≥ 4‑point reduction in the Pruritus Numerical Rating Scale). Quality‑of‑life gains were also evident, with a 6‑point improvement in the CDLQI.

The safety profile of lebrikizumab remained consistent with prior adult and adolescent data, with no injection‑site pain reported. These outcomes position the drug as the first and only selective IL‑13 inhibitor to demonstrate such robust results in a pediatric cohort, a demographic that accounts for a substantial proportion of the global AD burden.

Market Impact

The positive data are expected to reinforce investor confidence, as reflected in Almirall’s current valuation: a market capitalization of €2.44 billion and a price‑to‑earnings ratio of 53.58. Following the announcement, the share price closed at €11.36 on 12 March 2026, within a 52‑week range of €8.65 to €13.98. The company’s focus on dermatology, coupled with its strategic pipeline, aligns with industry trends favoring targeted biologics in chronic inflammatory skin diseases.

Geographic Expansion

In parallel with clinical advancements, Almirall has inaugurated a Shanghai office to accelerate research collaboration and regulatory engagement in China. The new facility will serve as a hub for biopharmaceutical innovation, enabling the company to leverage China’s rapidly expanding biotech ecosystem and to streamline access to emerging markets for its dermatology and CNS platforms.

Forward‑Looking Perspective

The ADorable‑1 results not only strengthen lebrikizumab’s development trajectory but also enhance Almirall’s competitive positioning against other IL‑13 and IL‑4/IL‑13 pathway inhibitors. With a clear regulatory pathway outlined for the U.S. and global authorities, the company is poised to pursue a label expansion that could unlock substantial revenue potential in pediatric AD.

Simultaneously, the Shanghai expansion signals a long‑term commitment to global growth. By embedding its operations within China’s vibrant scientific community, Almirall is strategically positioning itself to capture a larger share of the Asian dermatology market, which is expected to outpace growth in mature European and North American markets over the next decade.

In sum, Almirall’s recent clinical successes, coupled with targeted geographic expansion, underscore a robust growth engine grounded in scientific innovation and market acumen. The company’s trajectory suggests that it will continue to be a key player in the evolving landscape of dermatologic therapeutics, delivering both clinical value and shareholder returns.